Phosphatidylethanols (PEths) are specific, direct alcohol biomarkers with a substantially longer half-life than ethanol, and can be used to distinguish between heavy- and social drinking. More than forty PEth homologues have been detected in blood from heavy drinkers, and PEth 16:0/18:1 is the predominant one. Since PEths are phospholipids it can be difficult to isolate them from unwanted phospholipids during sample preparation. To minimize possible matrix effects it is therefore important to separate PEths from other phospholipids during LC-MS/MS analysis. In this study, we have investigated how the retention and chromatographic separation of eight PEth homologues and the phospholipid background are influenced by changes in mobile phase composition using two different LC columns, the Acquity BEH C18 column (50 × 2.1 mm ID, 1.7 µm particles) and the Kinetex biphenyl column (100 × 2.1 mm ID, 1.7 µm particles). Our findings show that the buffer concentration of the aqueous part of the mobile phase had a huge effect on the retention of PEth homologues and separation of PEths from unwanted phospholipids. By using a buffer-free mobile phase consisting of 0.025% ammonia in Type 1 water, pH 10.7, as solvent A and methanol as solvent B, all eight PEth homologues were separated from both the early eluting lyso-phospholipids and the later eluting phospholipids with two fatty chains using the BEH C18 column. The knowledge obtained in this study can be of great importance for those seeking to develop reliable and robust bioanalytical LC-MS/MS methods for determination of PEth homologues.
Alcohol consumption is associated with a wide risk of different diseases, injury and death, and has significant social and economic consequences worldwide. Phosphatidylethanol (PEth) is a group of promising direct alcohol biomarkers, with a significantly longer half-life in blood than ethanol, which can be measured to predict different drinking patterns, such as heavy- and social drinking. This study aimed to develop and validate an accurate and precise LC-MS/MS method for the determination of six PEth homologues in whole blood with minimal interference from unwanted phospholipids. Different organic solvent mixtures for liquid-liquid extraction were investigated to obtain satisfactory recovery of PEth homologues and removal of the lyso-phospholipids and other early eluting phospholipids. The mixture of heptane/2-propanol (80:20, v:v) gave lower phospholipid background and better signal/noise values for the PEth peaks. An LC-MS/MS TQ-S system from Waters was used for the instrumental analysis. The main part of unwanted phospholipids were separated from the PEth homologues on an Acquity BEH C18 column (50 × 2.1 mm ID, 1.7 µm particles) using a buffer-free mobile phase of 0.025 % ammonia in Type 1 water, pH 10.7, as solvent A and methanol as solvent B. Validation and quantification of 22 authentic blood samples showed that the developed LC-MS/MS method is sensitive, precise and accurate for the determination of the six PEth homologues in whole blood. Lower limit of quantification was 10 nM for all compounds. No matrix effects were observed, possibly due to the successful strategies incorporated to avoid the influence of unwanted phospholipids.
Background: Acidic mobile phases are commonly used in reversed phase liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalysis. However, increased sensitivity, improved peak symmetry, and increased retention, especially for basic hydrophilic drugs have been observed using basic mobile phases. In our previous acidic mobile phase LC-MS/MS method we needed two injections (0.4 and 2.0 mu L) of each sample for this task, which is inefficient. The aim of this study was to investigate if basic mobile phase LC-MS/MS could be used to determine phosphatidylethanol 16:0/18:1 and 20 other drugs and metabolites with satisfactory sensitivity in one single run. Methods: Whole blood was prepared by 96-well supported-liquid extraction using heptane/ethyl acetate/2propanol (16:64:20, v:v:v). Chromatographic separation was achieved on an Acquity BEH C-18 column (50 x 2.1 mm I.D.), using a mobile phase with 0.025 % ammonia, pH 10.7 (Solvent A) and methanol (Solvent B). All compounds had isotope-labelled internal standards. Results: The method was fully validated. Recovery was between 63 and 91 % for 20 compounds and 10 % for benzoylecgonine. Matrix effects were low, except for ion enhancement of buprenorphine and ion suppression for THC. However, internal standards compensated for these effects. Inter-assay precision and accuracy were < +/- 20 % for all compounds at five tested concentrations, except for methamphetamine at the highest concentration. Conclusion: An LC-MS/MS method for simultaneous determination of PEth 16:0/18:1 and 20 drugs and metabolites in whole blood were for the first time developed and validated. Retention of PEth 16:0/18:1 was, in contrast to the other 20 compounds, largely affected by mobile phase buffer concentration. The buffer free basic mobile phase ensured that phosphatidylethanol 16:0/18:1 eluted before most of the unwanted phospholipids.
10 January 2026 in Journal of Pharmaceutical and Biomedical Analysis
The use of alcohol, legal and illicit substances poses great negative consequences on health and economy worldwide. LC-MS/MS allow simultaneous determination of multiple compounds in biological matrices. The aim of this study was to develop a LC-MS/MS method for the determination of the alcohol biomarker phosphatidylethanol (PEth) - including three homologues (PEth 16:0/18:1, PEth 16:0/18:2, PEth 18:0/18:1) - cocaine and three metabolites, and 8 other drugs in whole blood. Whole blood in K2EDTA tubes was prepared by liquid-liquid extraction using heptane/ethyl acetate/2-propanol (16:64:20, v:v:v). Chromatographic separation was achieved on an Acquity BEH C18 column (50 × 2.1 mm I.D., 1.7 µm particles). Mobile phase was 0.025 % ammonia, pH 10.7 (Solvent A) and methanol (Solvent B). The method was fully validated with isotope-labelled internal standards for 10 compounds. Inter-assay precision and accuracy were within ± 16 % for all analytes at five to seven tested concentrations. Recovery was within 42-79 % for 14 compounds and 11 % for benzoylecgonine. Matrix effects were within ± 25 % for most analytes. Internal standards compensated for matrix effects for compounds that had their own internal standards. A robust, precise, and accurate LC-MS/MS method for the determinations of three PEth homologues and 12 drugs and metabolites was, developed and validated. The method is valuable, especially for detecting polydrug use and alcohol consumption. To the best of our knowledge, this is the first LC-MS/MS method for the simultaneous determination of three PEth homologues and different drugs and metabolites.
Over the past few years, the misuse of medications has progressively increased, posing a significant public health concern. This study proposed the development and validation of an alternative and greener analytical method for the determination of dextromethorphan (DXM) and its major metabolite, dextrorphan (DXO), in urine matrices using bar adsorptive microextraction (BAμE), followed by gas chromatography–mass spectrometry (GC-MS) analysis. Under optimized experimental conditions, average recoveries of 96.3% and 80.4% were achieved for DXM and DXO, respectively. The analytical limits obtained were 0.016 μg/mL for the limit of detection and 0.054 μg/mL for the limit of quantification. The working range was from 0.06 μg/mL to 2.0 μg/mL, with linearity for both compounds by determination coefficients (r2 > 0.99) and the goodness-of-fit and lack-of-fit tests. Intra-day precision and trueness yielded values below 8.77% and 16.28%, respectively, for both compounds. Inter-day precision and trueness values were below 7.67% and 9.73%, respectively. The application to 26 urine samples allowed the quantification of both compounds, with concentrations ranging from 0.06 to 3.21 μg/mL for DXM and 0.06 to 8.88 μg/mL for DXO. The method proved to be effective, selective, sensitive, simple, and cost-effective in the detection and quantification of DXM and DXO, reinforcing its applicability and feasibility in various laboratory contexts.
The present contribution proposes a new design for adsorptive microextraction devices that promote a user-friendly and greener analytical approach. Novel Sorbent Strip Microextraction (SSμE) devices were made using a flexible adhesive film coated with convenient sorbents. Comparing the previous adsorptive microextraction devices, i.e., bar adsorptive microextraction and multi-sphere adsorptive microextraction, the main advantage of the sorbent strip device is its simple design and reduced device preparation time and waste. To demonstrate its applicability, three opioids (buprenorphine, tapentadol, and tramadol) and two local anesthetics (articaine and bupivacaine) were used as model compounds in urine matrices, followed by high-performance liquid chromatography with diode array detector (HPLC-DAD) analysis. Key parameters such as sorbent type, desorption conditions, and microextraction variables were systematically optimized by experimental designs. Under the final conditions, the method achieved recoveries ranging from 78% to 108%, trueness within ±7% and precision expressed by relative standard deviation below 13%. The technique demonstrated good linearity (r2 ≥ 0.9922) across dynamic ranges of 5–500 ng/mL for local anesthetics and 50–5000 ng/mL for opioids. The validated SSμE/HPLC-DAD methodology was successfully applied to real urine samples, confirming its high precision and accuracy. The proposed microextraction technique offers a practical, eco-friendly, and effective alternative for routine drug screening in complex biological matrices and presents significant advantages over traditional and other microextraction-based methods.